Coronavirus Pandemic: An Update on the Transmission, Diagnosis, Clinical Features and Management

Saad S. Alqahtani¹,²*, Santhosh Joseph¹,²*, Otilia J. F. Banji¹,², Abdulkarim M. Meraya¹,², Ahmed A. Albarraq¹,², Hafiz A. Makeen¹,², David Banji¹,², Mamoon H. Syed¹,², Ayesha Yasmeen¹,², Ambreen Shoaib¹,², Nawazish Alam¹,², Khalid O. Alfarouk³,⁴, Nabeel Kashaan A. Syed¹,² and Sarfraz Ahmed¹,²

¹Department of Clinical Pharmacy, College of Pharmacy, Jazan University, Jazan, Saudi Arabia.
²Pharmacy Practice Research Unit, College of Pharmacy, Jazan University, Jazan, Saudi Arabia.
³Al-Ghad International College for Applied Medical Sciences, Al-Madinah Al-Munawarah, Saudi Arabia.
⁴Hala Alfarouk Cancer Center, Department of Evolutionary Pharmacology and Tumor Metabolism, Khartoum 11123, Sudan.

Authors' contributions

This work was carried out in collaboration among all authors. All authors read and approved the final manuscript.

ABSTRACT

The novel coronavirus, designated as “Severe Acute Respiratory Syndrome Coronavirus 2” (SARS-CoV-2), is a new coronavirus that has evolved as a global pandemic recently, and it has created a widespread interest in coronaviruses causing human infections. This article compares the pathogenesis, distribution, clinical characteristics, and treatment of the three highly pathogenic coronaviruses that caused epidemics, namely, “Severe Acute Respiratory Syndrome Coronavirus"
1. INTRODUCTION

Until a couple of decades ago, limited numbers of coronaviruses are considered to be relatively harmless human pathogens causing only trivial infections similar to common cold and cough.[1] However, with the start of the 21st century, outbreaks emerging periodically with a broad geographic spectrum caused by two highly pathogenic coronaviruses, namely, SARS-CoV and MERS-CoV, with the former causing severe acute respiratory syndrome or SARS outbreak in 2002 and the latter causing Middle East respiratory syndrome or MERS in 2012 have been reported.[2,3] This outbreak is followed by the novel coronavirus SARS-CoV-2, which appears toward the end of 2019 in Wuhan, China. SARS-CoV-2 has become the third major coronavirus affecting the human population. This viral pneumonia, which shares similar etiopathology, is the most frequent infectious disease that accounts for major clinical and socioeconomic impact worldwide, raising great public health concerns globally.

In late 2002, a number of beta-coronavirus-infected patients from Guangdong Province, China, were first identified with severe respiratory disease. It was accompanied with cases reported from neighboring countries such as Vietnam and even distant countries such as Canada. [4] The disease spread to communities and hospital facilities, and it was identified later as SARS in March 2003. This worldwide outbreak was contained by July 2003. [5]

MERS was the second coronavirus that caused infection, leading to a major global public health concern. MERS first emerged in 2012 in the Kingdom of Saudi Arabia (KSA), when a male patient died from acute severe pneumonia and renal impairment. [6] Subsequently, it caused an outbreak in 2014, where a total of 27 countries were affected, spanning across Europe, Asia, Middle East, and North America. In May 2015, another wave of MERS epidemic emerged when a South Korean man returned from the Middle East. [7]

The third major corona infection, SARS-CoV-2, was first identified in Wuhan, China, from where it crossed international borders to infect individuals in neighboring countries and then globally. Coronavirus Disease-2019 (COVID-19) is the term currently used to refer to the clinical disorders linked to SARS-CoV-2 infection as recommended by the World Health Organization (WHO). The virus was declared as a Public Health Emergency of International Concern by the WHO on 30 January 2020. COVID-19 is broadly described as a respiratory condition with a severity spectrum extending from insignificant signs to critically severe pneumonia cases and acute respiratory distress syndrome. Fatigue is complained by most of the patients. In addition, muscle or chest pain, headache, diarrhea, chills, abnormal smell or taste sensation, nausea, and confusion are observed in many patients. [8,9,10] “SARS-CoV,” “MERS-CoV,” and “SARS-CoV-2” share some similarities. These viruses belong to the same beta-coronavirus type, and they are positive-sense single-stranded enveloped RNA viruses, zoonotic coronaviruses, and transmitted interspecies (animal to human) and intraspecies (between humans, between animals).[11] In addition, COVID-19 seems to be associated with less severe infections compared with the other viruses; however, COVID-19 is quickly and widely transmitted in the population, whereas SARS and MERS are primarily associated with a nosocomial spread. [12]
The present review article aims to highlight the similarities and variabilities with regard to pathology, epidemiology, clinical manifestation, and treatment among COVID-19, SARS, and MERS. Moreover, this review aims to improve the understanding of the infections caused by these viruses and the antiviral treatment options for these coronavirus epidemics, particularly the current COVID-19 epidemic.

2. METHODOLOGY

Using the data compiled from WHO’s latest situation report, Centers for Disease Control and Prevention (CDC, USA) website, and literature reviews and research articles published in PubMed, Medline, ProQuest, and Google Scholar using the search MeSH terms “coronavirus,” “SARS-CoV,” “MERS-CoV,” “SARS-CoV-2,” “novel coronavirus,” and “COVID-19,” we collected information concerning epidemiology, clinical manifestations, pathophysiology, diagnosis, management, and related factors for MERS, SARS, and COVID-19.

2.1 Epidemiology

The worldwide SARS-CoV-2 spread spanned nearly over 220 countries/territories with the highest incidence in Europe, Indian subcontinent, and the Americas, with 183,934,913 confirmed cases and 3,985,022 deaths from late December 2019 until 6 July 2021, as reported by the WHO.[13] This result was significant as compared with that of SARS (spread to 32 countries with reports of 916 deaths from 8422 patients) and MERS-CoV (confirmed in more than 27 countries, resulting in 868 fatalities out of 2496 confirmed cases from April to Dec 2012; Table 1). COVID-19 is still in its diffusion stage with more than 500,000 people getting infected globally daily.[13] The COVID-19 situation in Saudi Arabia, at the time of this study (July 6th 2021) is standing with 494,032 confirmed cases with 7,891 deaths since the report of the first case of infection since March 2nd 2020.[13]

The patterns of SARS-CoV-2, SARS-CoV, and MERS-CoV infections seemed to have seasonal variations. A study on MERS reported that the outbreak primarily emerged during summer, with the highest global seasonal occurrence in the month of June. However, the COVID-19 and SARS infection outbreaks started or took place in the winter season.[15] The gender-based analysis of this novel coronavirus disease demonstrated no gender disparity in the number of patients to date; however, a male predominance in the vulnerability to this illness and in the fatality rate was observed.[16] The median age ranged from 50 to 65 years, with less than half of the patients possessing underlying comorbidities, including diabetes mellitus, hypertension, and different types of cardiovascular diseases.[10] The overall mortality rate was 2% at the start of the epidemic, which increased to 3.4% and in KSA, the overall mortality rate was stabilized below 1%.[17] A recent study in KSA has reported a case fatality rate (CFR) of 16% in hospitalized COVID-19 patients, which is lesser as compared with that of USA (21%), Italy (27%), and UK (33%).[18] However, MERS outbreak had a higher fatality rate (35%) among all diagnosed patients, and it often necessitated mechanical ventilation because of the severity of the illness (in 50%–89% of the cases).[7] According to a study outlining MERS cases, the mean age of all cases was 50 years (SD=±18), where over half of the cases reported having comorbidities, and 7.6% reported direct contact with a camel. In addition, these cases from the Saudi Arabian population showed male predominance. [19] SARS-CoV had an overall CFR of 11%. Women were predominant of those diagnosed with SARS, but they had a lower CFR than men (13.2% vs 22.3%). About half of the cases were younger than 40 years. Nearly 25% of the confirmed cases were healthcare workers with the lowest CFR (2%).[20]

Old age and underlying comorbidities, particularly respiratory ones, were identified as the predominant risk factors for the progression of these diseases.

2.2 Clinical Features and Diagnosis

In Table 2, the main clinical and biological features from typical SARS-CoV-2 patients were presented in comparison with the updated information on SARS and MERS. The COVID-19 patients had a mean age of 59 years, which was comparable to SARS and MERS; more than half of the COVID-19 cases had a chronic comorbidity but in a marginally less occurrence than MERS cases. Many asymptomatic patients were diagnosed with COVID-19 during screening of contacts. The typical presenting symptoms in most of the cases with mild to moderate COVID-19 infection were fever, dry cough, with or without sore throat and mild dyspnea; at least one symptom was being noted in most of the patients. Gastrointestinal symptoms, loss of smell and/or loss of taste were also being reported among COVID-19 patients. Patients
with severe disease may present with evidence of pneumonia (fever, shortness of breath, rapid breathing, rales in lungs, weakened breath sounds, dullness in the percussion, and oxygen saturation < 90% in room air).[21] Critically ill patients can rapidly develop acute respiratory distress syndrome (ARDS), or respiratory failure, multi-organ dysfunction syndromes, systemic manifestations (sepsis, septic shock), or multiple organ failure, with high risk for fatality.[9]

In KSA the median age was 36 years with nearly 10% being asymptomatic. Cough, fever, and sore throat were the most common symptoms reported in KSA.[22]

MERS might be suspected when a patient with a history of contact with probable or confirmed cases of the illness, or reported a history of travel or residence within the Arabian countries, presented with fever and cough, or hospitalization with possible lower respiratory tract involvement, although PCR-based techniques were still the preferred methods of confirmation of the diagnosis.[6,28]

SARS is diagnosed with a positive reverse transcription polymerase chain reaction (RT-PCR) test result from at least two specimens obtained from different locations or tested in different laboratories, from patients before or after death, or a seroconversion by enzyme-linked immunosorbent assays (ELISA).[29] The diagnosis of COVID-19 is achieved initially by assessing the clinical manifestations of the presenting patient, chest screening and excluding common bacterial and viral pneumonia, and then by obtaining specimens from the respiratory tract for culture and sequencing analysis or serological tests (anti-SARSr-CoV IgG and IgM antibody response testing ELISA kits with the antigen SARSr-CoV RP3 NP that shares more than 90% similarity to all SARSr-CoVs).[9,30]

Table 1. Comparison of epidemiological characteristics of MERS, SARS, and COVID-19

| Characteristics                  | SARS-CoV | MERS-CoV   | COVID-19* [13] |
|----------------------------------|----------|------------|----------------|
| Year of the outbreak             | 2002     | 2012       | 2019           |
| Country origin                   | Guangdong, China | Saudi Arabia | Wuhan, China  |
| Total confirmed cases            | 8422     | 2494       | 183,934,913    |
| Total deaths                     | 916 (10.87%) | 858 (34.77%) | 3,985,022 (2.16%) |
| Fatality rate                    | 9.19%    | 34.4%      | 0.1-25%**      |
| No. of affected countries/territories | 32      | 27         | 220            |

*: Current statistics (July 6th 2021) [13]
**: Widely variable estimates of case fatality rate (CFR) by country due to ongoing pandemic [14]

Table 2. Biological and clinical characteristics of coronaviruses

| Characteristics                  | COVID-19 [8,23] | SARS [24,25] | MERS [26,27] |
|----------------------------------|-----------------|--------------|--------------|
| Causative virus                  | SARS-CoV-2      | SARS-CoV     | MERS-CoV     |
| Biological characteristics       |                 |              |              |
| Incubation period                | 2–14 (5.2) days | 2–10 (7) days | 2–10 (5.5) days |
| Target receptors                 | Angiotensin-converting enzyme 2 (ACE2) | Angiotensin-converting enzyme 2 (ACE2) | Dipeptidyl peptidase-4 (DPP4) |
| Median age of patients           | 59 years        | 65 years     | 50 years     |
| Male/female                      | Male predominance | Male predominance | Male predominance |
| Origin/suspected source          | Seafood, Pangolins, Bats* | Bats, Civet cats | Bats, Camels |
| Speed of spread                  | High            | Moderate     | Low          |
| Season                           | Winter          | Winter       | Summer       |
| Clinical characteristics (% of cases) | >80              | >50          | >80          |
| Fever                            |                 |              |              |
| Cough                            | >50             | >55          | 55–85        |
| Shortness of breath              | 20–30           | 40           | 25–70        |
| Pharyngitis                      | 30              | 15–25        | 10           |
| Confusion                        | 20              | 5–43         | 5            |
| Diarrhea                         | 15              | 23–70        | 20–26        |

*: Several animals implicated but source still inconclusive
Laboratory tests in COVID-19 patients were similar to those of patients infected with other coronaviruses. All three viruses were definitively diagnosed by utilizing cultures of the respiratory fluids and serum antibody analysis or RT-PCR analysis of respiratory fluids from suspected patients. Non-specific findings of COVID-19 included lymphopenia (most frequent observation), often in combination with thrombocytopenia and hypoalbuminemia. In some cases, elevated creatine kinase, aminotransferase, C-reactive protein, and lactic dehydrogenase levels were recorded.[31]

All three viruses cause pneumonia, where a radiological presentation of the lungs is an important diagnostic tool for preliminary and broad identification of the severity of the disease. During early disease stages, chest x-rays have less sensitivity, not enough to detect these changes. However, computed tomography (CT) has better sensitivity for the detection of early or mild disease. Typical CT manifestations include ground-glass opacities (GGO), consolidation, and interlobular septal thickening. [32] CT imaging manifestations in COVID-19 patients can differ regarding disease stages and patients. In fact, in early stages, GGO with single or multiple lesions can be found in addition to the subpleural areas or bronchi.[33] On the other hand, severe patients might present bilateral multifocal consolidation, partially fused into massive consolidation with small pleural effusions and even manifesting with ‘white lung’. [34]

The radiological findings of the novel coronavirus have some similarities to the other two zoonotic coronaviruses; however, a higher rate of bilateral findings was found in patients with COVID-19. Xie X et al. suggested that 3% of the patients with suspected COVID-19 in Hubei Province had a CT screening that was confirmative of SARS-CoV-2 diagnosis but had a negative RT-PCR test result. These patients were treated in isolation, and the results turned positive for COVID-19 on repeated swab testing between 2 and 8 days later. [35]

2.3 Transmission

COVID-19 transmission was found to occur from person to person primarily through respiratory droplets when an infected patient coughs, sneezes, or speaks. The viral particles contaminate the objects and surfaces, which are transmitted by touch. In addition, the virus may be transmitted airborne; however, the transmission occurs primarily through droplets, contact, and fomites. Some reports have suggested the possibility of fecal–oral transmission, thereby indicating multiple routes of transmission. A person can be infected by breathing in the virus if that person is within a close distance (1–2 m) of an infected person or by touching a contaminated object or surface and then touching his face before washing the hands. The first cases of COVID-19 supposedly came from the seafood market in Hunan in China, with secondary cases occurring at hospitals among health care workers who came in contact with the infected patients.[10] MERS and SARS are also transmitted from close human-to-human contact through respiratory secretions from coughing and sneezing, whereas primary cases of MERS have been traced back to contact with infected camels, which was identified as the original reservoir host for MERS.[36] Other less common methods of transmission for SARS include fomites or fecal transmission and handling of animals such as bats.[2]

The spread of the novel coronavirus (COVID-19) is the fastest compared with the previous outbreak of coronaviruses, followed by SARS.

Even before the viral infection was formally declared a global pandemic, the Government of Saudi Arabia implemented preventative measures prior to any reported national deaths associated with COVID-19. The government imposed strict curfew, reinforced by financial penalties for anyone disregarding rules and constantly educated its citizens through mass media. Furthermore, Tawakkalna, a mobile application, was developed by the Ministry of Health and the Ministry of the Interior, to allow people to meet their needs and plan their journeys during the curfew period. [37]

2.4 Treatment

To date, the treatment of the novel coronavirus primarily involves isolation and supportive care to manage the symptoms or signs of clinical deterioration and providing respiratory assistance with oxygen therapy and ventilator support along with prophylactic antibiotics to prevent secondary infection. Anti-thrombotic such as heparin or low molecular-weight heparin may be given to patients with high thrombosis risk. [38] At present, no effective antiviral agent is available. Initial reports showed that oselantamivir was given to a large number of patients (150 mg/day) in combination with antibiotics such as azithromycin without any appreciable benefits. Corticosteroids
(dexamethasone 6 mg or methylprednisolone 40–120 mg/day equivalent) were given to patients requiring ventilator support to reduce lung inflammation caused by high levels of cytokines produced in response to the viral infection.[10] The monoclonal antibody targeting IL-6, tocilizumab (4–8 mg/kg as a single dose; repeated after 12 h as necessary), has also been found to be beneficial in the management of patients that have cytokine release syndrome.[39,40] Researchers have previously described the prophylactic use of chloroquine and its therapeutic benefits during the SARS-CoV outbreak. In vitro activity of hydroxychloroquine against COVID-19 showed apparent clinical efficacy. [41,42] The use of hydroxychloroquine (400–800 mg per day for 5 days) in the management of COVID-19 cases remains debatable and requires additional clinical evidence. Early intravenous infusion of human immunoglobulin may be recommended as a rescue treatment for critically ill patients based on their clinical condition. [43]

Remdesivir (200 mg intravenous loading dose followed by once daily 100 mg infusions for 5–10 days), an Ebola-antiviral drug, with its broad range of antiviral activity in vitro and in animal studies against numerous RNA viruses, including coronaviruses (SARS and MERS), showed potential as an anti-COVID-19 medication [40,44] and clinical improvement in non-randomized compassionate use cohorts. [45] On 22 October 2020, the USFDA released an update stating that remdesivir was approved for treating hospitalized COVID-19 patients (adult and pediatric) aged 12 years and above.[46] However, on 20 November 2020, the WHO released an advisory with a conditional recommendation, which opposed the usage of remdesivir irrespective of the severity in patients hospitalized with COVID-19.[47] The lopinavir/ritonavir therapy (400 mg lopinavir/ritonavir twice daily for 6–10 days) has been recommended by health authorities of several countries; however, recent studies from China and United Kingdom report no efficacy with lopinavir/ritonavir treatment versus the usual therapeutic care.[48,49] In an experimental study, favipiravir showed significantly higher treatment benefits for COVID-19 in contrast to lopinavir/ritonavir, and it is used 3600 mg/day in two divided doses on the first day followed by 1600 mg/day in two divided doses for 7–10 days.[50] Finally, type 1 interferons (interferon β-1b 8 million units every 48 h for three doses) with or without ribavirin (800 mg/day) could be considered as a treatment against COVID-19 but mostly in the early phases of the disease.[51] Combinations of the above mentioned agents have been recommended by various health agencies in their treatment protocols. Triple regimen involving lopinavir/ritonavir, ribavirin, and interferon β-1b for 14 days was recommended in many countries such as Hong Kong and the KSA.[40] Baricitinib (a janus kinase inhibitor) at a dose of 4 mg per day for 14 days in combination with remdesivir was found to be superior to remdesivir alone in a randomized double-blind trial.[52]

After trials with various medications and based on the experiences from various countries and studies, the treatment protocol in KSA was continuously updated to the current protocol. The treatment protocol in KSA recommends use of favipiravir or remdesivir along with systemic steroids (dexamethasone/ hydrocortisone/prednisolone) in severe cases while critically ill patients are recommended remdesivir alone or in combination with baricitinib along with the systemic steroids. Patients experiencing rapid deterioration in respiratory function may be offered tocilizumab with systemic steroids. Thromboprophylaxis is recommended in all admitted patients after evaluation for bleeding risk. Patients with mild to moderate respiratory symptoms may be offered favipiravir or inhaled budesonide according to the discretion of the treating physician. [53]

The main focus of the treatment for SARS-CoV-2 was the isolation of infected subjects, antivirals, and supportive treatments. Combination therapy of lopinavir/ritonavir was beneficial with fewer adverse clinical outcomes. [54] A clinical study in the KSA showed that lopinavir/ritonavir combined with interferon beta-1b was effective among MERS cases along with supportive care. [55]

2.5 Preventive vaccines

Vaccine research in MERS and SARS is still in its early stages of clinical evaluation, and a number of vaccines for COVID-19 have been fast tracked for approval in various countries. There is a concern that, as with natural coronavirus infection, vaccination may not induce long-lived immunity and hence re-infection or breakthrough infections may be possible.[56]

In USA, two mRNA-based vaccines have been authorized for use, BNT162b2 or tozinameran an mRNA-1273. BNT162b2 showed 95% efficacy
against symptomatic COVID-19, whereas mRNA-1273 vaccine showed 94.1% efficacy, and both vaccines showed acceptable safety profile in clinical trials.[57,58] The United Kingdom approved ChAdOx1 nCoV-19 or AZD1222 for emergency use. ChAdOx1 nCoV-19 vaccine efficacy ranged from 60% to 95%.[59] Other vaccines that were authorized for early emergency use included inactivated BBIBP-CorV vaccine in China and Adenovirus-based Sputnik V vaccine in Russia, which showed promising results in early studies. [60, 61]

BNT162b2 and ChAdOx1 nCoV-19 were given emergency approval for vaccination in KSA with 2nd dose recommended after 42 days of the first dose. As of 27 June 2021, a total of 18,495,398 vaccine doses have been administered to the Saudi population as reported by WHO.[13]

The vaccines have not undergone long-term studies, a requisite to assess the long-term side effects and safety, which is very much a cause of concern. Currently reported common side effects following COVID 19 vaccinations were generally mild and included injection site reactions, headache, muscle pain, fatigue, arthralgia, fever and chills and allergic reactions including anaphylaxis. [57,58,59]

3. DISCUSSION

The infection moved from China to Europe and North Americas to Latin American countries, Africa, and the Indian Subcontinent and then back to Europe for a second round, and based on the trends of the global spread of the disease, the disease may do another round in several countries unless preventive measures are continued. The Americas, Europe, and United Kingdom are currently at the epicenter of the pandemic. The lack of adequate testing facilities and access to health care is a major concern in many countries. The current statistics may be only a fraction of the actual figures because of the poor testing facilities, fewer tests, documentation, and transparency in COVID-19 data in many countries. Thus, governments must be prepared to face the outbreak by strategic planning. Systematic lockdown with social distancing is currently the most effective way of slowing down disease transmission. Such measures will remain as the primary measure for disease control until sufficient quantity of effective vaccines can be produced to vaccinate a significant part of the population—worldwide. Adequate risk evaluation, considering the seriousness of the current setting and prompt dissemination of outbreak-related information, can provide comprehensive understanding of the pandemic dynamics and help us slacken the spread of SARS-CoV-2 worldwide. [62]

The infection rates among healthcare professionals are high during the outbreaks of MERS and SARS, particularly those involved in high-risk procedures such as intubation and endotracheal suction.[63,64] This result is similar to that of COVID-19, which has affected the medical practice and functioning of hospitals during the current coronavirus outbreak. Furthermore, the novel coronavirus is transmitted to healthcare workers, although comparisons with MERS and SARS have not yet made.

Meticulous monitoring and supportive care can reduce the risk of mortality in COVID-19; however, such care cannot be offered to all patients when a large number of patients are infected with the virus. The use of steroids and tocilizumab may be beneficial in critically ill patients with lung involvement by modulating the cytokine-mediated inflammatory responses; however, tocilizumab is an expensive option for widespread use. In the current scenario of non-availability of a specific antiviral agent, potential medications (as suggested by in vitro studies or based on experience with other coronavirus infections) for COVID-19 with less serious side effects along with good supportive care can be considered. A logical approach in the management of symptomatic COVID-19 patients is the combination of safe agents. Currently reported results are based on observational studies or studies that are not conducted in randomized control settings. Several factors such as timing of initiation of antiviral therapy, concomitant use of other antiviral drugs, potential antiviral enhancing/suppressing effect of other concomitant medications, severity of illness, or severity of comorbid illness may influence the outcomes of antiviral therapy. These factors should be considered before accepting any positive or negative results being reported currently as a recommendation. Adopting treatment protocols from countries with significant number of cases but with significantly low mortality rate is another option, which may be considered until more concrete evidence emerges regarding antiviral therapy.

Mass vaccinations and building vaccine-acquired herd immunity are potential approaches for containing the infection; however, mass
production of vaccines to provide adequate supply of vaccines is a great challenge that the manufacturers are facing. However, questions still remain regarding the long-term side effects and duration of the protective efficacy of the preventive vaccines developed and approved in such a short time frame.

Studies have shown mutations of the novel coronavirus genome, and some mutations have become more aggressive and contagious; this mutation may be an outcome of natural evolution. Similar mutations in the spike (S) protein are found during the initial phase of the SARS 2002–2003 epidemic, which eventually dominates the outbreak, concluding new adaptations to humans. The spread of COVID-19 widely across the Middle East also raises concerns about MERS and COVID-19 co-infection in human or animals with possible emergence of new strains of coronavirus.

4. CONCLUSION

The experiences from previous outbreaks of SARS and MERS and from the countries affected initially with COVID-19 are the best lessons currently available as there is a lot to known about COVID-19. Although we have a number of potential antiviral medications for COVID-19, more extensive studies and analyses are needed before strong recommendations can be made for or against any particular treatment. Unlike MERS and SARS, novel coronavirus SARS-CoV-2 is highly contagious, and proper hygiene and protocols for limiting human-to-human transmission along with improved epidemiologic surveillance and monitoring are recommended to reduce viral transmission until vaccines are available for mass vaccination programs.

DISCLAIMER

The products used for this research are commonly and predominantly use products in our area of research and country. There is absolutely no conflict of interest between the authors and producers of the products because we do not intend to use these products as an avenue for any litigation but for the advancement of knowledge. Also, the research was not funded by the producing company rather it was funded by personal efforts of the authors.

CONSENT

It is not applicable.

ETHICAL APPROVAL

It is not applicable.

COMPETING INTERESTS

Authors have declared that no competing interests exist.

REFERENCES

1. Yin Y, Wunderink RG. MERS, SARS and other coronaviruses as causes of pneumonia. Respirology 2018;23:130–7.
2. Chan-Yeung M, Xu R-H. SARS: Epidemiology. Respirology 2003;8:S9-14.
3. Zaki AM, van Boheemen S, Bestebroer TM, Osterhaus ADME, Fouchier RAM. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med 2012;367:1814-20.
4. Ksiazek TG, Erdman D, Goldsmith CS, Zaki SR, Peret T, Emery S, et al. A novel coronavirus associated with severe acute respiratory syndrome. N Engl J Med 2003;348:1953–66.
5. Anderson RM, Fraser C, Ghani AC, Donnelly CA, Riley S, Ferguson NM, et al. Epidemiology, transmission dynamics and control of SARS: the 2002-2003 epidemic. Philos Trans R Soc Lond B Biol Sci 2004;359:1091–105.
6. Mackay IM, Arden KE. MERS coronavirus: diagnostics, epidemiology and transmission. Virol J 2015;12:222.
7. Wit E de, Doremalen N van, Falzarano D, Munster VJ. SARS and MERS: recent insights into emerging coronaviruses. Nat Rev Microbiol 2016;14:523–34.
8. CDC.gov [homepage on the Internet]. Coronavirus Disease 2019 (COVID-19) – Symptoms. Centers for Disease Control and Prevention. Available:https://www.cdc.gov/coronavirus/2019-ncov/symptoms-testing/symptoms.html. [updated 2021 Feb 22; Last accessed 2021 July 6]
9. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet 2020;395:497–506.
10. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med 2020;382:727–33.
11. Chen Y, Liu Q, Guo D. Emerging coronaviruses: Genome structure, replication, and pathogenesis. J Med Virol. 2020;92:418–23.

12. Munster VJ, Koopmans M, van Doremalen N, van Riel D, de Wit E. A Novel Coronavirus Emerging in China — Key Questions for Impact Assessment. N Engl J Med. 2020;382:692–4.

13. WHO.int [homepage on the Internet]. COVID-19 Dashboard. World Health Organization. Available: https://covid19.who.int/ [updated daily; Last accessed 2021 July 6]

14. WHO.int [homepage on the Internet]. Estimating mortality from COVID-19. Available: https://www.who.int/news-room/commentaries/detail/estimating-mortality-from-covid-19. [updated 2020 Aug 4; Last accessed 2021 July 6]

15. Meo SA, Alhowikam AN, Al-Khaiwi TI, Meo IM, Halepotra DM, Iqbal M, et al. Novel coronavirus 2019-nCoV: prevalence, biological and clinical characteristics comparison with SARS-CoV and MERS-CoV. Eur Rev Med Pharmacol Sci. 2020;24:2012–9.

16. Novel Coronavirus Pneumonia Emergency Response Epidemiology Team. [The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China]. Zhonghua Liu Xing Bing Xue Za Zhi. 2020;41:145–51.

17. Alberto Boretti. COVID-19 fatality rate for Saudi Arabia, updated 8 August 2020. J Glob Antimicrob Resist 2020;23:329–30.

18. Khan AA, AlRuthia Y, Balkhi B, Alghadheer SM, Temsah MH, Althunayyan SM et al. Survival and Estimation of Direct Medical Costs of Hospitalized COVID-19 Patients in the Kingdom of Saudi Arabia. Int J Environ Res Public Health 2020;17:7458. DOI: 10.3390/ijerph17027458.

19. Rivers CM, Majumder MS, Lofgren ET. Risks of death and severe disease in patients with Middle East Respiratory Syndrome coronavirus, 2012-2015. Am J Epidemiol 2016;184:460–4.

20. Leung GM, Hedley AJ, Ho L-M, Chau P, Wong IOL, Thach TQ, et al. The epidemiology of severe acute respiratory syndrome in the 2003 Hong Kong epidemic: an analysis of all 1755 patients. Ann Intern Med 2004;141:662–73.

21. Guo Y-R, Cao Q-D, Hong Z-S, Tan Y-Y, Chen S-D, Jin H-J, et al. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak – an update on the status. Mil Med Res 2020;7:11.

22. Alsofayan YM, Althunayyan SM, Khan AA, Hakawi AM, Assiri AM. Clinical characteristics of COVID-19 in Saudi Arabia: A national retrospective stud. J of Infection and Public Health 2020; 13(7):920-5.

23. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA 2020; 323:1061–9.

24. Hui DSC, Zumla A. Severe Acute Respiratory Syndrome: Historical, Epidemiologic, and Clinical Features. Infect Dis Clin North Am 2019;33:869–89.

25. Lee N, Hui D, Wu A, Chan P, Cameron P, Joynt GM, et al. A major outbreak of severe acute respiratory syndrome in Hong Kong. N Engl J Med 2003;348:1986–94.

26. Choi WS, Kang C-I, Kim Y, Choi J-P, Joh JS, Shin H-S, et al. Clinical Presentation and Outcomes of Middle East Respiratory Syndrome in the Republic of Korea. Infect Chemother 2016;48:118–26.

27. Saad M, Omrani AS, Baig K, Bahoul A, Elzein F, Matin MA, et al. Clinical aspects and outcomes of 70 patients with Middle East respiratory syndrome coronavirus infection: a single-center experience in Saudi Arabia. Int J Infect Dis 2014;29:301–6.

28. Nassar MS, Bakhrebah MA, Meo SA, Alsauabeyl MS, Zaher WA. Middle East Respiratory Syndrome Coronavirus (MERS-CoV) infection: epidemiology, pathogenesis and clinical characteristics. Eur Rev Med Pharmacol Sci. 2018;22:4956–61.

29. Emery SL, Erdman DD, Bowen MD, Newton BR, Winchell JM, Meyer RF, et al. Real-time reverse transcription-polymerase chain reaction assay for SARS-associated coronavirus. Emerg Infect Dis 2004;10(2):311–6.

30. Zhou P, Yang X-L, Wang X-G, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 2020;579:270–3.
a descriptive study. Lancet 2020;395:507–13.
32. Alsharif W, Qurasli A. Effectiveness of COVID-19 diagnosis and management tools: A review. Radiography (Lond) 2021;27(2):682–7.
33. Zhao W, Zhong Z, Xie X, Yu Q, Liu J. Relation Between Chest CT Findings and Clinical Conditions of Coronavirus Disease (COVID-19) Pneumonia: A Multicenter Study. AJR Am J Roentgenol 2020;214(5):1072–7.
34. Zu ZY, Jiang MD, Xu PP, Chen W, Ni QQ, Lu GM, et al. Coronavirus Disease 2019 (COVID-19): A Perspective from China. Radiology 2020;296(2):E15–25.
35. Xie X, Zhong Z, Zhao W, Zheng C, Wang F, Liu J. Chest CT for Typical 2019-nCoV Pneumonia: Relationship to Negative RT-PCR Testing. Radiology 2020;200343.
36. WHO.int [homepage on the Internet]. Middle East respiratory syndrome coronavirus (MERS-CoV). World Health Organization. Available:https://www.who.int/health-topics/middle-east-respiratory-syndrome-coronavirus-mers [Last accessed 2021 July 6]
37. AL-Rasheedi M, Alhazmi Y, Mateq Ali Al, ALrajhi M, Alharbi NS, Alsuaibani S, et al. Public and healthcare providers awareness of Coronavirus (COVID-19) in Qassim Region, Saudi Arabia. Saudi J Biol Sci 2021;28(1):90–8.
38. WHO.int [homepage on the Internet]. COVID-19 Clinical management: living guidance. Available:https://www.who.int/publications/i/item/WHO-2019-nCoV-clinical-2021-1. [updated 2021 Jan 25; Last accessed 2021 July 6]
39. Luo P, Liu Y, Qiu L, Liu X, Liu D, Li J. Tocilizumab Treatment in COVID-19: A Single Center Experience. J Med Virol 2020;92:814-8.
40. Hung IF, Lung KC, Tso EY, Liu R, Chung TW, Chu MY et al. Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial. Lancet. 2020;395:1695-1704.
41. Chen Z, Hu J, Zhang Z, Jiang S, Han S, Yan D, et al. Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial. Med Rxiv; 2020. Available:https://doi.org/10.1101/2020.03.2 2.20040758.
42. Yao X, Ye F, Zhang M, Cui C, Huang B, Niu P, et al. In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Clin Infect Dis; 2020. https://doi.org/10.1093/cid/ciaa237.
43. Chen L, Xiong J, Bao L, Shi Y. Convalescent plasma as a potential therapy for COVID-19. Lancet Infect Dis 2020;20(4):398–400.
44. Agostini ML, Andres EL, Sims AC, Graham RL, Sheahan TP, Lu X, et al. Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclelease. mBio. 2018;9.
45. Grein J, Ohmagari N, Shin D, Diaz G, Asperges E, Castagna A, et al. Compassionate Use of Remdesivir for Patients with Severe Covid-19. N Engl J Med. 2020;382:2327-36.
46. FDA.gov [homepage on the Internet]. FDA Approves First Treatment for COVID-19. Available:https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-covid-19 [Released 2020 Oct 22; Last accessed 2021 Jan 29]
47. WHO.int [homepage on the Internet]. WHO recommends against the use of remdesivir in COVID-19 patients. Available:https://www.who.int/news-room/feature-stories/detail/who-recommends-against-the-use-of-remdesivir-in-covid-19-patients [Released 2020 Nov 20; Last accessed 2021 July 6]
48. Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, et al. A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. N Engl J Med 2020;382(19):1787-99.
49. Horby PW, Matham M, Bell JL, Linsell L, Staplin N, Emberson J, et al. Lopinavir–ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2020;19(20):1-8.
50. Cai Q, Yang M, Liu D, Chen J, Shu D, Xia J, et al. Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study. Engineering; 2020. Available:https://doi.org/10.1016/j.eng.2020.03.007.
51. Sallard E, Lescure F-X, Yazdanpanah Y, Mentre F, Peiffer-Smadelj N. Type 1 interferons as a potential treatment against COVID-19. Antiviral Res 2020;178:104791.

52. Kalil AC, Patterson TF, Mehta AK, Tomashek KM, Wolfe CR, Ghazaryan V, et al. Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19. N Engl J Med 2021;384(9):795-807.

53. MOH.gov.sa [homepage on the Internet]. Saudi MoH Protocol for Patients Suspected of/Confirmed with COVID-19. Available:https://www.moh.gov.sa/Ministry/MediaCenter/Publications/Documents/MOHtherapeutic-protocol-for-COVID-19.pdf. [Updated 2021 May 29; Last accessed 2021 July 6]

54. Chu CM, Cheng VCC, Hung IFN, Wong MML, Chan KH, Chan KS, et al. Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings. Thorax 2004;59:252–6.

55. Arabi YM, Althooman A, Balkhy HH, Al-Dawood A, AlJohani S, Al Harbi S, et al. Treatment of Middle East Respiratory Syndrome with a combination of lopinavir-ritonavir and interferon-β1b (MIRACLE trial): study protocol for a randomized controlled trial. Trials 2018;19:81.

56. Roper RL, Rehm KE. SARS vaccines: where are we? Expert Rev Vaccines 2009;8(7):887–98.

57. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020;383(27):2603-15.

58. Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med. 2020;383(27):2603-15.

59. Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021;397(10269):99–111.

60. Xia S, Zhang Y, Wang Y, Wang H, Yang Y, Gao GF, et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial. Lancet Infect Dis. 2021;21(1):39-51.

61. Logunov DY, Dolzhikova IV, Zubkova OV, Tukhvatulin AI, Shcheblyakov DV, Dzharaullaev AS et al. Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia. Lancet. 2020;396(10255):887-897.

62. Peeri NC, Shrestha N, Rahman MS, Zaki R, Tan Z, Bibi S, et al. The SARS, MERS and novel coronavirus (COVID-19) epidemics, the newest and biggest global health threats: what lessons have we learned? Int J Epidemiol; 2020. https://doi.org/10.1093/ije/dyaa033.

63. Malave A, Elamin EM. Severe Acute Respiratory Syndrome (SARS)-Lessons for Future Pandemics. Virtual Mentor 2010;12:719–25.

64. Park J-E, Jung S, Kim A, Park J-E. MERS transmission and risk factors: a systematic review. BMC Public Health, 2018;18:574.

65. Tang X, Wu C, Li X, Song Y, Yao X, Wu X, et al. On the origin and continuing evolution of SARS-CoV-2. Natl Sci Rev; 2020. Available:https://doi.org/10.1093/nsr/nwaa036.

66. Consortium TCSME. Molecular Evolution of the SARS Coronavirus During the Course of the SARS Epidemic in China. Science. 2004;303:1666–9.